Frontlight ResearchEarly access
Trial site
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
- 5running trials
- 4closed trials
The trials here
What the 9 trials at this site are about, from their registry records.
- Conditions
- Bladder cancer2 trials
- Colorectal cancer2 trials
- Head and neck cancer2 trials
- Lung cancer2 trials
- Metastatic breast cancer2 trials
- Pancreatic cancer2 trials
- Triple-negative breast cancer2 trials
- Cervical cancer1 trial
- Childhood cancers1 trial
- Gastric and oesophageal cancer1 trial
- Multiple myeloma1 trial
- Ovarian cancer1 trial
- Phase
- Phase 25 trials
- Phase 12 trials
- Phase 32 trials
- Status
- Active, not recruiting3 trials
- Completed3 trials
- Recruiting2 trials
- Withdrawn1 trial
- Lead sponsor
- Pfizer5 trials
- Seagen, a wholly owned subsidiary of Pfizer3 trials
- Dana-Farber Cancer Institute1 trial
Running trials
Active, not recruiting
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Active, not recruiting
Recruiting
Active, not recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Bladder cancer2 recruiting
- Cervical cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Head and neck cancer1 recruiting
- Lung cancer1 recruiting
- Ovarian cancer1 recruiting
- Pancreatic cancer1 recruiting
Closed trials
Recruiting
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Completed
Completed
Completed
Site data: ClinicalTrials.govUpdated 12 Nov 2026